Spasticity: Clinical Trials

3 trials for Spasticity, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated. 3 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Terminated 3
Phase 32Terminated 2
Phase 11Terminated 1

Follow Spasticity: new trials by email Literature Review of Spasticity trials Research Report on Spasticity

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident
Phase 2 / Phase 3TerminatedSolstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC322021-11-022026-05-27
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity
Phase 2 / Phase 3TerminatedSolstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC402019-12-172026-05-22
One Year Extension Study To Protocol C2/5/TZ:MS-05
sublingual tizanidine 12 mg - Spasticity, Multiple Sclerosis
Phase 1 / Phase 2TerminatedTeva GTC102008-01-012009-02-19

Narrower conditions

Muscle Spasticity (3)  ·  Brain Injuries, Traumatic (2)  ·  Hemiplegia (2)  ·  Multiple Sclerosis (2)  ·  Stroke (2)  ·  Cerebral Palsy (1)  ·  Fatigue (1)

Broader conditions

Muscle Hypertonia (3)  ·  Muscular Diseases (3)  ·  Musculoskeletal Diseases (3)  ·  Nervous System Diseases (3)  ·  Neurologic Manifestations (3)  ·  Neuromuscular Manifestations (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Signs and Symptoms (3)  ·  Autoimmune Diseases (2)  ·  Autoimmune Diseases of the Nervous System (2)  ·  Brain Diseases (2)  ·  Brain Injuries (2)  ·  Cardiovascular Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Cerebrovascular Disorders (2)

Interventions

Clinical Trials, Phase II as Topic (2)  ·  Clinical Trials, Phase III as Topic (2)  ·  rimabotulinumtoxinB (2)

Sponsors

Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC (2)  ·  Teva GTC (1)

Countries

Hungary (2)  ·  Poland (2)  ·  United States (2)  ·  Israel (1)

Top investigators

Joseph T Hull, PhD (2)  ·  Arnon Karni, MD (1)